TG Therapeutics Receives a Buy from H.C. Wainwright

By Carrie Williams

H.C. Wainwright analyst Edward White assigned a Buy rating to TG Therapeutics (NASDAQ: TGTX) today and set a price target of $33. The company’s shares closed yesterday at $8.25.

According to, White is a 5-star analyst with an average return of 16.8% and a 48.8% success rate. White covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics Inc, Syndax Pharmaceuticals Inc, and Spectrum Pharmaceuticals.

TG Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $26.

Based on TG Therapeutics’ latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $38.1K and GAAP net loss of $31.54 million. In comparison, last year the company earned revenue of $38.1K and had a GAAP net loss of $24.83 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. It also involves developing TG-1101 and TGR-1202 therapies targeting hematological malignancies. The company was founded by Michael Sean Weiss and Laurence H.